Cargando…

Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy

This study aimed to investigate the impact of indoleamine 2,3-dioxygenase 1 (IDO1) expression, programmed cell death-ligand 1 (PD-L1) expression, CD8+ tumor-infiltrating lymphocyte (TIL) status, and their combination on pathologic complete response (pCR) and recurrence in esophageal squamous cell ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Sha, Zhao, Lei, Liang, Zhaohui, Liu, Songran, Li, Yong, Liu, Shiliang, Yang, Hong, Liu, Mengzhong, Xi, Mian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406509/
https://www.ncbi.nlm.nih.gov/pubmed/30717285
http://dx.doi.org/10.3390/cancers11020169
_version_ 1783401321912598528
author Zhou, Sha
Zhao, Lei
Liang, Zhaohui
Liu, Songran
Li, Yong
Liu, Shiliang
Yang, Hong
Liu, Mengzhong
Xi, Mian
author_facet Zhou, Sha
Zhao, Lei
Liang, Zhaohui
Liu, Songran
Li, Yong
Liu, Shiliang
Yang, Hong
Liu, Mengzhong
Xi, Mian
author_sort Zhou, Sha
collection PubMed
description This study aimed to investigate the impact of indoleamine 2,3-dioxygenase 1 (IDO1) expression, programmed cell death-ligand 1 (PD-L1) expression, CD8+ tumor-infiltrating lymphocyte (TIL) status, and their combination on pathologic complete response (pCR) and recurrence in esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (CRT). Indoleamine 2,3-dioxygenase 1, PD-L1, and CD8+ TIL statuses were evaluated by immunohistochemical analysis on pre-CRT biopsies of 158 patients. Sixty-eight patients (43.0%) achieved pCR after neoadjuvant CRT and 48 patients (30.4%) developed recurrences after surgery. IDO1 and PD-L1 proteins were co-expressed in 28 patients (17.7%). Indoleamine 2,3-dioxygenase 1 positive patients showed a significantly lower pCR rate than IDO1 negative patients (28.6% vs. 51.0%, P = 0.007). Similarly, PD-L1 high expression was significantly negatively correlated with pCR rate (27.3% vs. 51.5%, P = 0.004). On multivariate analysis, IDO1 expression was an independent prognostic factor for developing recurrences. Stratification analysis revealed that patients with co-expression of IDO1 and PD-L1 were significantly associated with a lower pCR rate and worse recurrence-free survival than those with one or none positive protein. In conclusion, IDO1 and PD-L1 co-expression could predict poor pathologic response and high risk of recurrence in ESCC after neoadjuvant CRT, indicating a subset of patients who may benefit from CRT combined with immunotherapy.
format Online
Article
Text
id pubmed-6406509
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64065092019-03-21 Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy Zhou, Sha Zhao, Lei Liang, Zhaohui Liu, Songran Li, Yong Liu, Shiliang Yang, Hong Liu, Mengzhong Xi, Mian Cancers (Basel) Article This study aimed to investigate the impact of indoleamine 2,3-dioxygenase 1 (IDO1) expression, programmed cell death-ligand 1 (PD-L1) expression, CD8+ tumor-infiltrating lymphocyte (TIL) status, and their combination on pathologic complete response (pCR) and recurrence in esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (CRT). Indoleamine 2,3-dioxygenase 1, PD-L1, and CD8+ TIL statuses were evaluated by immunohistochemical analysis on pre-CRT biopsies of 158 patients. Sixty-eight patients (43.0%) achieved pCR after neoadjuvant CRT and 48 patients (30.4%) developed recurrences after surgery. IDO1 and PD-L1 proteins were co-expressed in 28 patients (17.7%). Indoleamine 2,3-dioxygenase 1 positive patients showed a significantly lower pCR rate than IDO1 negative patients (28.6% vs. 51.0%, P = 0.007). Similarly, PD-L1 high expression was significantly negatively correlated with pCR rate (27.3% vs. 51.5%, P = 0.004). On multivariate analysis, IDO1 expression was an independent prognostic factor for developing recurrences. Stratification analysis revealed that patients with co-expression of IDO1 and PD-L1 were significantly associated with a lower pCR rate and worse recurrence-free survival than those with one or none positive protein. In conclusion, IDO1 and PD-L1 co-expression could predict poor pathologic response and high risk of recurrence in ESCC after neoadjuvant CRT, indicating a subset of patients who may benefit from CRT combined with immunotherapy. MDPI 2019-02-01 /pmc/articles/PMC6406509/ /pubmed/30717285 http://dx.doi.org/10.3390/cancers11020169 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhou, Sha
Zhao, Lei
Liang, Zhaohui
Liu, Songran
Li, Yong
Liu, Shiliang
Yang, Hong
Liu, Mengzhong
Xi, Mian
Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
title Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
title_full Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
title_fullStr Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
title_full_unstemmed Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
title_short Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
title_sort indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression predicts poor pathologic response and recurrence in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406509/
https://www.ncbi.nlm.nih.gov/pubmed/30717285
http://dx.doi.org/10.3390/cancers11020169
work_keys_str_mv AT zhousha indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy
AT zhaolei indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy
AT liangzhaohui indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy
AT liusongran indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy
AT liyong indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy
AT liushiliang indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy
AT yanghong indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy
AT liumengzhong indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy
AT ximian indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy